- Home
- LEGH vs URGN Comparison
LEGH vs URGN Comparison
Compare LEGH & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- URGN
- Stock Information
- Founded
- LEGH 2005
- URGN 2004
- Country
- LEGH United States
- URGN United States
- Employees
- LEGH N/A
- URGN N/A
- Industry
- LEGH Homebuilding
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- URGN Health Care
- Exchange
- LEGH Nasdaq
- URGN Nasdaq
- Market Cap
- LEGH 601.1M
- URGN 547.1M
- IPO Year
- LEGH 2018
- URGN 2017
- Fundamental
- Price
- LEGH $25.18
- URGN $11.04
- Analyst Decision
- LEGH Buy
- URGN Strong Buy
- Analyst Count
- LEGH 2
- URGN 5
- Target Price
- LEGH $29.00
- URGN $44.50
- AVG Volume (30 Days)
- LEGH 67.1K
- URGN 363.8K
- Earning Date
- LEGH 11-12-2024
- URGN 11-06-2024
- Dividend Yield
- LEGH N/A
- URGN N/A
- EPS Growth
- LEGH N/A
- URGN N/A
- EPS
- LEGH 2.18
- URGN N/A
- Revenue
- LEGH $163,718,000.00
- URGN $89,363,000.00
- Revenue This Year
- LEGH N/A
- URGN $13.39
- Revenue Next Year
- LEGH $8.19
- URGN $45.06
- P/E Ratio
- LEGH $11.50
- URGN N/A
- Revenue Growth
- LEGH N/A
- URGN 15.64
- 52 Week Low
- LEGH $19.42
- URGN $10.26
- 52 Week High
- LEGH $29.31
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- LEGH 47.29
- URGN 39.89
- Support Level
- LEGH $23.92
- URGN $10.26
- Resistance Level
- LEGH $25.43
- URGN $11.67
- Average True Range (ATR)
- LEGH 0.61
- URGN 0.51
- MACD
- LEGH -0.01
- URGN -0.08
- Stochastic Oscillator
- LEGH 61.46
- URGN 32.23
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.